The good and the bad faces of STAT1 in solid tumours

Cytokine

Volumn 89, Issue , 2017, Pages 12-20

  Meissl, Katrin ^a   Macho Maschler, Sabine ^a   Müller, Mathias ^a   Strobl, Birgit ^a  

^a UNIVERSITY OF VETERINARY MEDICINE   (Austria)

Author keywords

Acquired therapy resistance; Cell proliferation and death; Cytokine signalling; Immune surveillance; Tumour suppressor

Indexed keywords

STAT1 PROTEIN; STAT1 PROTEIN, HUMAN; TUMOR SUPPRESSOR PROTEIN;

ADAPTIVE IMMUNITY; ANTIANGIOGENIC ACTIVITY; CANCER GROWTH; CANCER IMMUNOEDITING; CANCER INHIBITION; CANCER RESISTANCE; CARCINOGENESIS; CELL DEATH; CELL GROWTH; DNA DAMAGE; HUMAN; IMMUNE EVASION; INNATE IMMUNITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REVIEW; SOLID TUMOR; TUMOR IMMUNITY; TUMOR INVASION; ANIMAL; GENETICS; IMMUNOLOGY; NEOPLASM; PATHOLOGY; SIGNAL TRANSDUCTION;

ADAPTIVE IMMUNITY; ANIMALS; HUMANS; IMMUNITY, INNATE; NEOPLASMS; SIGNAL TRANSDUCTION; STAT1 TRANSCRIPTION FACTOR; TUMOR SUPPRESSOR PROTEINS;

EID: 84949681428     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2015.11.011     Document Type: Review

References (159)

1. [1] Copeland, N.G., Gilbert, D.J., Schindler, C., Zhong, Z., Wen, Z., Darnell, J.E. Jr., et al. Distribution of the mammalian Stat gene family in mouse chromosomes. Genomics 29 (1995), 225–228.
2. [2] Decker, T., Stockinger, S., Karaghiosoff, M., Muller, M., Kovarik, P., IFNs and STATs in innate immunity to microorganisms. J. Clin. Invest. 109 (2002), 1271–1277.
3. [3] Boisson-Dupuis, S., Kong, X.F., Okada, S., Cypowyj, S., Puel, A., Abel, L., et al. Inborn errors of human STAT1: allelic heterogeneity governs the diversity of immunological and infectious phenotypes. Curr. Opin. Immunol. 24 (2012), 364–378.
4. [4] Najjar, I., Fagard, R., STAT1 and pathogens, not a friendly relationship. Biochimie 92 (2010), 425–444.
5. [5] Vignali, D.A., Kuchroo, V.K., IL-12 family cytokines: immunological playmakers. Nat. Immunol. 13 (2012), 722–728.
6. [6] Decker, T., Kovarik, P., Serine phosphorylation of STATs. Oncogene 19 (2000), 2628–2637.
7. [7] Kohanbash, G., Okada, H., MicroRNAs and STAT interplay. Semin. Cancer Biol. 22 (2012), 70–75.
8. [8] Semper, C., Leitner, N.R., Lassnig, C., Parrini, M., Mahlakoiv, T., Rammerstorfer, M., et al. STAT1beta is not dominant negative and is capable of contributing to gamma interferon-dependent innate immunity. Mol. Cell Biol. 34 (2014), 2235–2248.
9. [9] Cheon, H., Yang, J., Stark, G.R., The functions of signal transducers and activators of transcriptions 1 and 3 as cytokine-inducible proteins. J. Interferon Cytokine Res. 31 (2011), 33–40.
10. [10] Meyer, T., Begitt, A., Lodige, I., van Rossum, M., Vinkemeier, U., Constitutive and IFN-gamma-induced nuclear import of STAT1 proceed through independent pathways. EMBO J. 21 (2002), 344–354.
11. [11] Santos, C.I., Costa-Pereira, A.P., Signal transducers and activators of transcription-from cytokine signalling to cancer biology. Biochim. Biophys. Acta 1816 (2011), 38–49.
12. [12] Shi, S., Calhoun, H.C., Xia, F., Li, J., Le, L., Li, W.X., JAK signaling globally counteracts heterochromatic gene silencing. Nat. Genet. 38 (2006), 1071–1076.
13. [13] Brown, S., Zeidler, M.P., Unphosphorylated STATs go nuclear. Curr. Opin. Genet. Dev. 18 (2008), 455–460.
14. [14] Meyer, T., Gavenis, K., Vinkemeier, U., Cell type-specific and tyrosine phosphorylation-independent nuclear presence of STAT1 and STAT3. Exp. Cell Res. 272 (2002), 45–55.
15. [15] Silver-Morse, L., Li, W.X., JAK-STAT in heterochromatin and genome stability. JAKSTAT, 2, 2013, e26090.
16. [16] Bohmer, F.D., Friedrich, K., Protein tyrosine phosphatases as wardens of STAT signaling. JAKSTAT, 3, 2014, e28087.
17. [17] Croker, B.A., Kiu, H., Nicholson, S.E., SOCS regulation of the JAK/STAT signalling pathway. Semin. Cell Dev. Biol. 19 (2008), 414–422.
18. [18] Porritt, R.A., Hertzog, P.J., Dynamic control of type I IFN signalling by an integrated network of negative regulators. Trends Immunol. 36 (2015), 150–160.
19. [19] Reich, N.C., STATs get their move on. JAKSTAT, 2, 2013, e27080.
20. [20] Rytinki, M.M., Kaikkonen, S., Pehkonen, P., Jaaskelainen, T., Palvimo, J.J., PIAS proteins: pleiotropic interactors associated with SUMO. Cell Mol. Life Sci. 66 (2009), 3029–3041.
21. [21] Boisson, B., Quartier, P., Casanova, J.L., Immunological loss-of-function due to genetic gain-of-function in humans: autosomal dominance of the third kind. Curr. Opin. Immunol. 32 (2015), 90–105.
22. [22] Casanova, J.L., Holland, S.M., Notarangelo, L.D., Inborn errors of human JAKs and STATs. Immunity 36 (2012), 515–528.
23. [23] Gordziel, C., Bratsch, J., Moriggl, R., Knosel, T., Friedrich, K., Both STAT1 and STAT3 are favourable prognostic determinants in colorectal carcinoma. Br. J. Cancer 109 (2013), 138–146.
24. [24] Klampfer, L., The role of signal transducers and activators of transcription in colon cancer. Front Biosci. 13 (2008), 2888–2899.
25. [25] Simpson, J.A., Al-Attar, A., Watson, N.F., Scholefield, J.H., Ilyas, M., Durrant, L.G., Intratumoral T cell infiltration, MHC class I and STAT1 as biomarkers of good prognosis in colorectal cancer. Gut 59 (2010), 926–933.
26. [26] Slattery, M.L., Lundgreen, A., Kadlubar, S.A., Bondurant, K.L., Wolff, R.K., JAK/STAT/SOCS-signaling pathway and colon and rectal cancer. Mol. Carcinog. 52 (2013), 155–166.
27. [27] Chen, G., Wang, H., Xie, S., Ma, J., Wang, G., STAT1 negatively regulates hepatocellular carcinoma cell proliferation. Oncol. Rep. 29 (2013), 2303–2310.
28. [28] Zhang, Y., Molavi, O., Su, M., Lai, R., The clinical and biological significance of STAT1 in esophageal squamous cell carcinoma. BMC Cancer., 14, 2014, 791.
29. [29] Sun, Y., Yang, S., Sun, N., Chen, J., Differential expression of STAT1 and p21 proteins predicts pancreatic cancer progression and prognosis. Pancreas 43 (2014), 619–623.
30. [30] Takahashi, A., Nakayama, R., Ishibashi, N., Doi, A., Ichinohe, R., Ikuyo, Y., et al. Analysis of gene expression profiles of soft tissue sarcoma using a combination of knowledge-based filtering with integration of multiple statistics. PLoS ONE, 9, 2014, e106801.
31. [31] Osborn, J.L., Greer, S.F., Metastatic melanoma cells evade immune detection by silencing STAT1. Int. J. Mol. Sci. 16 (2015), 4343–4361.
32. [32] Widschwendter, A., Tonko-Geymayer, S., Welte, T., Daxenbichler, G., Marth, C., Doppler, W., Prognostic significance of signal transducer and activator of transcription 1 activation in breast cancer. Clin. Cancer Res. 8 (2002), 3065–3074.
33. [33] Tymoszuk, P., Charoentong, P., Hackl, H., Spilka, R., Muller-Holzner, E., Trajanoski, Z., et al. High STAT1 mRNA levels but not its tyrosine phosphorylation are associated with macrophage infiltration and bad prognosis in breast cancer. BMC Cancer, 14, 2014, 257.
34. [34] Sheen-Chen, S.M., Huang, C.C., Tang, R.P., Yang, C.H., Chou, F.F., Eng, H.L., Signal transducer and activator of transcription 1 in breast cancer: analysis with tissue microarray. Anticancer Res. 27 (2007), 2481–2486.
35. [35] Chan, S.R., Vermi, W., Luo, J., Lucini, L., Rickert, C., Fowler, A.M., et al. STAT1-deficient mice spontaneously develop estrogen receptor alpha-positive luminal mammary carcinomas. Breast Cancer Res., 14, 2012, R16.
36. [36] Kim, J.H., Kang, H.S., Kim, T.W., Kim, S.J., Differential methylation hybridization profiling identifies involvement of STAT1-mediated pathways in breast cancer. Int. J. Oncol. 39 (2011), 955–963.
37. [37] Klover, P.J., Muller, W.J., Robinson, G.W., Pfeiffer, R.M., Yamaji, D., Hennighausen, L., Loss of STAT1 from mouse mammary epithelium results in an increased Neu-induced tumor burden. Neoplasia 12 (2010), 899–905.
38. [38] Raven, J.F., Williams, V., Wang, S., Tremblay, M.L., Muller, W.J., Durbin, J.E., et al. Stat1 is a suppressor of ErbB2/Neu-mediated cellular transformation and mouse mammary gland tumor formation. Cell Cycle 10 (2011), 794–804.
39. [39] Schneckenleithner, C., Bago-Horvath, Z., Dolznig, H., Neugebauer, N., Kollmann, K., Kolbe, T., et al. Putting the brakes on mammary tumorigenesis: loss of STAT1 predisposes to intraepithelial neoplasias. Oncotarget 2 (2011), 1043–1054.
40. [40] Bailey, S.G., Cragg, M.S., Townsend, P.A., Role of STAT1 in the breast. JAKSTAT 1 (2012), 197–199.
41. [41] Koromilas, A.E., Sexl, V., The tumor suppressor function of STAT1 in breast cancer. JAKSTAT, 2, 2013, e23353.
42. [42] Kaplan, D.H., Shankaran, V., Dighe, A.S., Stockert, E., Aguet, M., Old, L.J., et al. Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc. Natl. Acad. Sci. USA 95 (1998), 7556–7561.
43. [43] Bromberg, J.F., Activation of STAT proteins and growth control. BioEssays 23 (2001), 161–169.
44. [44] Bromberg, J.F., Horvath, C.M., Wen, Z., Schreiber, R.D., Darnell, J.E. Jr., Transcriptionally active Stat1 is required for the antiproliferative effects of both interferon alpha and interferon gamma. Proc. Natl. Acad. Sci. USA 93 (1996), 7673–7678.
45. [45] Kim, H.S., Lee, M.S., STAT1 as a key modulator of cell death. Cell Signal 19 (2007), 454–465.
46. [46] Lasfar, A., Abushahba, W., Balan, M., Cohen-Solal, K.A., Interferon lambda: a new sword in cancer immunotherapy. Clin. Dev. Immunol., 2011, 2011, 349575.
47. [47] Chin, Y.E., Kitagawa, M., Su, W.C., You, Z.H., Iwamoto, Y., Fu, X.Y., Cell growth arrest and induction of cyclin-dependent kinase inhibitor p21 WAF1/CIP1 mediated by STAT1. Science 272 (1996), 719–722.
48. [48] Mandal, M., Bandyopadhyay, D., Goepfert, T.M., Kumar, R., Interferon-induces expression of cyclin-dependent kinase-inhibitors p21WAF1 and p27Kip1 that prevent activation of cyclin-dependent kinase by CDK-activating kinase (CAK). Oncogene 16 (1998), 217–225.
49. [49] Hobeika, A.C., Etienne, W., Torres, B.A., Johnson, H.M., Subramaniam, P.S., IFN-gamma induction of p21(WAF1) is required for cell cycle inhibition and suppression of apoptosis. J. Interferon Cytokine Res. 19 (1999), 1351–1361.
50. [50] Wang, S., Raven, J.F., Durbin, J.E., Koromilas, A.E., Stat1 phosphorylation determines Ras oncogenicity by regulating p27 kip1. PLoS ONE, 3, 2008, e3476.
51. [51] Kortylewski, M., Komyod, W., Kauffmann, M.E., Bosserhoff, A., Heinrich, P.C., Behrmann, I., Interferon-gamma-mediated growth regulation of melanoma cells: involvement of STAT1-dependent and STAT1-independent signals. J. Invest. Dermatol. 122 (2004), 414–422.
52. [52] Dimco, G., Knight, R.A., Latchman, D.S., Stephanou, A., STAT1 interacts directly with cyclin D1/Cdk4 and mediates cell cycle arrest. Cell Cycle 9 (2010), 4638–4649.
53. [53] Bretones, G., Delgado, M.D., Leon, J., Myc and cell cycle control. Biochim. Biophys. Acta 1849 (2015), 506–516.
54. [54] Ramana, C.V., Grammatikakis, N., Chernov, M., Nguyen, H., Goh, K.C., Williams, B.R., et al. Regulation of c-myc expression by IFN-gamma through Stat1-dependent and -independent pathways. EMBO J. 19 (2000), 263–272.
55. [55] Schmitt, M.J., Philippidou, D., Reinsbach, S.E., Margue, C., Wienecke-Baldacchino, A., Nashan, D., et al. Interferon-gamma-induced activation of Signal Transducer and Activator of Transcription 1 (STAT1) up-regulates the tumor suppressing microRNA-29 family in melanoma cells. Cell Commun. Signal, 10, 2012, 41.
56. [56] Cory, S., Adams, J.M., The Bcl2 family: regulators of the cellular life-or-death switch. Nat. Rev. Cancer 2 (2002), 647–656.
57. [57] Ossina, N.K., Cannas, A., Powers, V.C., Fitzpatrick, P.A., Knight, J.D., Gilbert, J.R., et al. Interferon-gamma modulates a p53-independent apoptotic pathway and apoptosis-related gene expression. J. Biol. Chem. 272 (1997), 16351–16357.
58. [58] Stephanou, A., Brar, B.K., Scarabelli, T.M., Jonassen, A.K., Yellon, D.M., Marber, M.S., et al. Ischemia-induced STAT-1 expression and activation play a critical role in cardiomyocyte apoptosis. J. Biol. Chem. 275 (2000), 10002–10008.
59. [59] Cao, Z.H., Zheng, Q.Y., Li, G.Q., Hu, X.B., Feng, S.L., Xu, G.L., et al. STAT1-mediated down-regulation of Bcl-2 expression is involved in IFN-gamma/TNF-alpha-induced apoptosis in NIT-1 cells. PLoS ONE, 10, 2015, e0120921.
60. [60] Chin, Y.E., Kitagawa, M., Kuida, K., Flavell, R.A., Fu, X.Y., Activation of the STAT signaling pathway can cause expression of caspase 1 and apoptosis. Mol. Cell Biol. 17 (1997), 5328–5337.
61. [61] Bernabei, P., Coccia, E.M., Rigamonti, L., Bosticardo, M., Forni, G., Pestka, S., et al. Interferon-gamma receptor 2 expression as the deciding factor in human T, B, and myeloid cell proliferation or death. J. Leukoc. Biol. 70 (2001), 950–960.
62. [62] Egwuagu, C.E., Li, W., Yu, C.R., Che Mei Lin, M., Chan, C.C., Nakamura, T., et al. Interferon-gamma induces regression of epithelial cell carcinoma: critical roles of IRF-1 and ICSBP transcription factors. Oncogene 25 (2006), 3670–3679.
63. [63] Liedtke, C., Groger, N., Manns, M.P., Trautwein, C., Interferon-alpha enhances TRAIL-mediated apoptosis by up-regulating caspase-8 transcription in human hepatoma cells. J. Hepatol. 44 (2006), 342–349.
64. [64] Kumar, A., Commane, M., Flickinger, T.W., Horvath, C.M., Stark, G.R., Defective TNF-alpha-induced apoptosis in STAT1-null cells due to low constitutive levels of caspases. Science 278 (1997), 1630–1632.
65. [65] Shin, E.C., Ahn, J.M., Kim, C.H., Choi, Y., Ahn, Y.S., Kim, H., et al. IFN-gamma induces cell death in human hepatoma cells through a TRAIL/death receptor-mediated apoptotic pathway. Int. J. Cancer 93 (2001), 262–268.
66. [66] Xu, X., Fu, X.Y., Plate, J., Chong, A.S., IFN-gamma induces cell growth inhibition by Fas-mediated apoptosis: requirement of STAT1 protein for up-regulation of Fas and FasL expression. Cancer Res. 58 (1998), 2832–2837.
67. [67] Miura, Y., Tsujioka, T., Nishimura, Y., Sakaguchi, H., Maeda, M., Hayashi, H., et al. TRAIL expression up-regulated by interferon-gamma via phosphorylation of STAT1 induces myeloma cell death. Anticancer Res. 26 (2006), 4115–4124.
68. [68] Meng, R.D., El-Deiry, W.S., P53-independent upregulation of KILLER/DR5 TRAIL receptor expression by glucocorticoids and interferon-gamma. Exp. Cell Res. 262 (2001), 154–169.
69. [69] Choi, E.A., Lei, H., Maron, D.J., Wilson, J.M., Barsoum, J., Fraker, D.L., et al. Stat1-dependent induction of tumor necrosis factor-related apoptosis-inducing ligand and the cell-surface death signaling pathway by interferon beta in human cancer cells. Cancer Res. 63 (2003), 5299–5307.
70. [70] Rani, M.R., Pandalai, S., Shrock, J., Almasan, A., Ransohoff, R.M., Requirement of catalytically active Tyk2 and accessory signals for the induction of TRAIL mRNA by IFN-beta. J. Interferon Cytokine Res. 27 (2007), 767–779.
71. [71] Papageorgiou, A., Dinney, C.P., McConkey, D.J., Interferon-alpha induces TRAIL expression and cell death via an IRF-1-dependent mechanism in human bladder cancer cells. Cancer Biol. Ther. 6 (2007), 872–879.
72. [72] Oshima, K., Yanase, N., Ibukiyama, C., Yamashina, A., Kayagaki, N., Yagita, H., et al. Involvement of TRAIL/TRAIL-R interaction in IFN-alpha-induced apoptosis of Daudi B lymphoma cells. Cytokine 14 (2001), 193–201.
73. [73] Suk, K., Chang, I., Kim, Y.H., Kim, S., Kim, J.Y., Kim, H., et al. Interferon gamma (IFNgamma) and tumor necrosis factor alpha synergism in ME-180 cervical cancer cell apoptosis and necrosis. IFNgamma inhibits cytoprotective NF-kappa B through STAT1/IRF-1 pathways. J. Biol. Chem. 276 (2001), 13153–13159.
74. [74] Tomita, Y., Bilim, V., Hara, N., Kasahara, T., Takahashi, K., Role of IRF-1 and caspase-7 in IFN-gamma enhancement of Fas-mediated apoptosis in ACHN renal cell carcinoma cells. Int. J. Cancer 104 (2003), 400–408.
75. [75] Thomas, M., Finnegan, C.E., Rogers, K.M., Purcell, J.W., Trimble, A., Johnston, P.G., et al. STAT1: a modulator of chemotherapy-induced apoptosis. Cancer Res. 64 (2004), 8357–8364.
76. [76] Koike, K., Takaki, A., Tatsukawa, M., Suzuki, M., Shiraha, H., Iwasaki, Y., et al. Combination of 5-FU and IFNalpha enhances IFN signaling pathway and caspase-8 activity, resulting in marked apoptosis in hepatoma cell lines. Int. J. Oncol. 29 (2006), 1253–1261.
77. [77] Patt, Y.Z., Hassan, M.M., Lozano, R.D., Brown, T.D., Vauthey, J.N., Curley, S.A., et al. Phase II trial of systemic continuous fluorouracil and subcutaneous recombinant interferon Alfa-2b for treatment of hepatocellular carcinoma. J. Clin. Oncol. 21 (2003), 421–427.
78. [78] Acquavella, N., Clever, D., Yu, Z., Roelke-Parker, M., Palmer, D.C., Xi, L., et al. Type I cytokines synergize with oncogene inhibition to induce tumor growth arrest. Cancer Immunol. Res. 3 (2015), 37–47.
79. [79] Baran-Marszak, F., Feuillard, J., Najjar, I., Le Clorennec, C., Bechet, J.M., Dusanter-Fourt, I., et al. Differential roles of STAT1alpha and STAT1beta in fludarabine-induced cell cycle arrest and apoptosis in human B cells. Blood 104 (2004), 2475–2483.
80. [80] Townsend, P.A., Scarabelli, T.M., Davidson, S.M., Knight, R.A., Latchman, D.S., Stephanou, A., STAT-1 interacts with p53 to enhance DNA damage-induced apoptosis. J. Biol. Chem. 279 (2004), 5811–5820.
81. [81] Cheok, C.F., Verma, C.S., Baselga, J., Lane, D.P., Translating p53 into the clinic. Nat. Rev. Clin. Oncol. 8 (2011), 25–37.
82. [82] Soussi, T., Wiman, K.G., TP53: an oncogene in disguise. Cell Death Differ. 22 (2015), 1239–1249.
83. [83] Najjar, I., Schischmanoff, P.O., Baran-Marszak, F., Deglesne, P.A., Youlyouz-Marfak, I., Pampin, M., et al. Novel function of STAT1beta in B cells: induction of cell death by a mechanism different from that of STAT1alpha. J. Leukoc. Biol. 84 (2008), 1604–1612.
84. [84] Wang, Y., Wu, T.R., Cai, S., Welte, T., Chin, Y.E., Stat1 as a component of tumor necrosis factor alpha receptor 1-TRADD signaling complex to inhibit NF-kappaB activation. Mol. Cell Biol. 20 (2000), 4505–4512.
85. [85] Marino, G., Niso-Santano, M., Baehrecke, E.H., Kroemer, G., Self-consumption: the interplay of autophagy and apoptosis. Nat. Rev. Mol. Cell Biol. 15 (2014), 81–94.
86. [86] White, E., Deconvoluting the context-dependent role for autophagy in cancer. Nat. Rev. Cancer 12 (2012), 401–410.
87. [87] Li, P., Du, Q., Cao, Z., Guo, Z., Evankovich, J., Yan, W., et al. Interferon-gamma induces autophagy with growth inhibition and cell death in human hepatocellular carcinoma (HCC) cells through interferon-regulatory factor-1 (IRF-1). Cancer Lett. 314 (2012), 213–222.
88. [88] Yan, J., Wang, Z.Y., Yang, H.Z., Liu, H.Z., Mi, S., Lv, X.X., et al. Timing is critical for an effective anti-metastatic immunotherapy: the decisive role of IFNgamma/STAT1-mediated activation of autophagy. PLoS One, 6, 2011, e24705.
89. [89] Mittal, D., Gubin, M.M., Schreiber, R.D., Smyth, M.J., New insights into cancer immunoediting and its three component phases–elimination, equilibrium and escape. Curr. Opin. Immunol. 27 (2014), 16–25.
90. [90] Fallarino, F., Gajewski, T.F., Cutting edge: differentiation of antitumor CTL in vivo requires host expression of Stat1. J. Immunol. 163 (1999), 4109–4113.
91. [91] Lee, C.K., Rao, D.T., Gertner, R., Gimeno, R., Frey, A.B., Levy, D.E., Distinct requirements for IFNs and STAT1 in NK cell function. J. Immunol. 165 (2000), 3571–3577.
92. [92] Putz, E.M., Gotthardt, D., Hoermann, G., Csiszar, A., Wirth, S., Berger, A., et al. CDK8-mediated STAT1-S727 phosphorylation restrains NK cell cytotoxicity and tumor surveillance. Cell Rep. 4 (2013), 437–444.
93. [93] Robbins, S.H., Tessmer, M.S., Van Kaer, L., Brossay, L., Direct effects of T-bet and MHC class I expression, but not STAT1, on peripheral NK cell maturation. Eur. J. Immunol. 35 (2005), 757–765.
94. [94] Mizutani, T., Neugebauer, N., Putz, E.M., Moritz, N., Simma, O., Zebedin-Brandl, E., et al. Conditional IFNAR1 ablation reveals distinct requirements of Type I IFN signaling for NK cell maturation and tumor surveillance. Oncoimmunology 1 (2012), 1027–1037.
95. [95] Prchal-Murphy, M., Witalisz-Siepracka, A., Bednarik, K.T., Putz, E.M., Gotthardt, D., Meissl, K., et al. Tumor surveillance by NK cells requires TYK2 but not TYK2 kinase activity. Oncoimmunology, 4, 2015, e1047579.
96. [96] Wu, X., Chen, Y., Sun, R., Wei, H., Tian, Z., Impairment of hepatic NK cell development in IFN-gamma deficient mice. Cytokine 60 (2012), 616–625.
97. [97] Diamond, M.S., Kinder, M., Matsushita, H., Mashayekhi, M., Dunn, G.P., Archambault, J.M., et al. Type I interferon is selectively required by dendritic cells for immune rejection of tumors. J. Exp. Med. 208 (2011), 1989–2003.
98. [98] Fuertes, M.B., Kacha, A.K., Kline, J., Woo, S.R., Kranz, D.M., Murphy, K.M., et al. Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8{alpha}+ dendritic cells. J. Exp. Med. 208 (2011), 2005–2016.
99. [99] Leibowitz, M.S., Andrade Filho, P.A., Ferrone, S., Ferris, R.L., Deficiency of activated STAT1 in head and neck cancer cells mediates TAP1-dependent escape from cytotoxic T lymphocytes. Cancer Immunol. Immunother. 60 (2011), 525–535.
100. [100] Lee, C.K., Gimeno, R., Levy, D.E., Differential regulation of constitutive major histocompatibility complex class I expression in T and B lymphocytes. J. Exp. Med. 190 (1999), 1451–1464.
101. [101] Shankaran, V., Ikeda, H., Bruce, A.T., White, J.M., Swanson, P.E., Old, L.J., et al. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 410 (2001), 1107–1111.
102. [102] Leibowitz, M.S., Srivastava, R.M., Andrade Filho, P.A., Egloff, A.M., Wang, L., Seethala, R.R., et al. SHP2 is overexpressed and inhibits pSTAT1-mediated APM component expression, T-cell attracting chemokine secretion, and CTL recognition in head and neck cancer cells. Clin. Cancer Res. 19 (2013), 798–808.
103. [103] Baeriswyl, V., Christofori, G., The angiogenic switch in carcinogenesis. Semin. Cancer Biol. 19 (2009), 329–337.
104. [104] Bergers, G., Hanahan, D., Modes of resistance to anti-angiogenic therapy. Nat. Rev. Cancer 8 (2008), 592–603.
105. [105] Battle, T.E., Lynch, R.A., Frank, D.A., Signal transducer and activator of transcription 1 activation in endothelial cells is a negative regulator of angiogenesis. Cancer Res. 66 (2006), 3649–3657.
106. [106] Nielsen, S.R., Hammer, T., Gibson, J., Pepper, M.S., Nisato, R.E., Dissing, S., et al. IL-27 inhibits lymphatic endothelial cell proliferation by STAT1-regulated gene expression. Microcirculation 20 (2013), 555–564.
107. [107] Salvucci, O., Ohnuki, H., Maric, D., Hou, X., Li, X., Yoon, S.O., et al. EphrinB2 controls vessel pruning through STAT1-JNK3 signalling. Nat. Commun., 6, 2015, 6576.
108. [108] Huang, S., Bucana, C.D., Van Arsdall, M., Fidler, I.J., Stat1 negatively regulates angiogenesis, tumorigenicity and metastasis of tumor cells. Oncogene 21 (2002), 2504–2512.
109. [109] Kachroo, P., Lee, M.H., Zhang, L., Baratelli, F., Lee, G., Srivastava, M.K., et al. IL-27 inhibits epithelial-mesenchymal transition and angiogenic factor production in a STAT1-dominant pathway in human non-small cell lung cancer. J. Exp. Clin. Cancer Res., 32, 2013, 97.
110. [110] Shen, H., Lentsch, A.B., Progressive dysregulation of transcription factors NF-kappa B and STAT1 in prostate cancer cells causes proangiogenic production of CXC chemokines. Am. J. Physiol. Cell Physiol. 286 (2004), C840–C847.
111. [111] Hiroi, M., Mori, K., Sakaeda, Y., Shimada, J., Ohmori, Y., STAT1 represses hypoxia-inducible factor-1-mediated transcription. Biochem. Biophys. Res. Commun. 387 (2009), 806–810.
112. [112] Watson, C.J., Miller, W.R., Elevated levels of members of the STAT family of transcription factors in breast carcinoma nuclear extracts. Br. J. Cancer. 71 (1995), 840–844.
113. [113] Hix, L.M., Karavitis, J., Khan, M.W., Shi, Y.H., Khazaie, K., Zhang, M., Tumor STAT1 transcription factor activity enhances breast tumor growth and immune suppression mediated by myeloid-derived suppressor cells. J. Biol. Chem. 288 (2013), 11676–11688.
114. [114] Greenwood, C., Metodieva, G., Al-Janabi, K., Lausen, B., Alldridge, L., Leng, L., et al. Stat1 and CD74 overexpression is co-dependent and linked to increased invasion and lymph node metastasis in triple-negative breast cancer. J. Proteomics. 75 (2012), 3031–3040.
115. [115] Zimmerman, M.A., Rahman, N.T., Yang, D., Lahat, G., Lazar, A.J., Pollock, R.E., et al. Unphosphorylated STAT1 promotes sarcoma development through repressing expression of Fas and bad and conferring apoptotic resistance. Cancer Res. 72 (2012), 4724–4732.
116. [116] Wong, G.S., Lee, J.S., Park, Y.Y., Klein-Szanto, A.J., Waldron, T.J., Cukierman, E., et al. Periostin cooperates with mutant p53 to mediate invasion through the induction of STAT1 signaling in the esophageal tumor microenvironment. Oncogenesis, 2, 2013, e59.
117. [117] Forys, J.T., Kuzmicki, C.E., Saporita, A.J., Winkeler, C.L., Maggi, L.B. Jr., Weber, J.D., ARF and p53 coordinate tumor suppression of an oncogenic IFN-beta-STAT1-ISG15 signaling axis. Cell Rep. 7 (2014), 514–526.
118. [118] Malilas, W., Koh, S.S., Kim, S., Srisuttee, R., Cho, I.R., Moon, J., et al. Cancer upregulated gene 2, a novel oncogene, enhances migration and drug resistance of colon cancer cells via STAT1 activation. Int. J. Oncol. 43 (2013), 1111–1116.
119. [119] Khodarev, N., Ahmad, R., Rajabi, H., Pitroda, S., Kufe, T., McClary, C., et al. Cooperativity of the MUC1 oncoprotein and STAT1 pathway in poor prognosis human breast cancer. Oncogene 29 (2010), 920–929.
120. [120] Kufe, D.W., Mucins in cancer: function, prognosis and therapy. Nat. Rev. Cancer 9 (2009), 874–885.
121. [121] Andrianifahanana, M., Agrawal, A., Singh, A.P., Moniaux, N., van Seuningen, I., Aubert, J.P., et al. Synergistic induction of the MUC4 mucin gene by interferon-gamma and retinoic acid in human pancreatic tumour cells involves a reprogramming of signalling pathways. Oncogene 24 (2005), 6143–6154.
122. [122] Andrianifahanana, M., Singh, A.P., Nemos, C., Ponnusamy, M.P., Moniaux, N., Mehta, P.P., et al. IFN-gamma-induced expression of MUC4 in pancreatic cancer cells is mediated by STAT-1 upregulation: a novel mechanism for IFN-gamma response. Oncogene 26 (2007), 7251–7261.
123. [123] Seshacharyulu, P., Ponnusamy, M.P., Rachagani, S., Lakshmanan, I., Haridas, D., Yan, Y., et al. Targeting EGF-receptor(s) – STAT1 axis attenuates tumor growth and metastasis through downregulation of MUC4 mucin in human pancreatic cancer. Oncotarget 6 (2015), 5164–5181.
124. [124] Kusmartsev, S., Gabrilovich, D.I., STAT1 signaling regulates tumor-associated macrophage-mediated T cell deletion. J. Immunol. 174 (2005), 4880–4891.
125. [125] Alvaro, T., Lejeune, M., Camacho, F.I., Salvado, M.T., Sanchez, L., Garcia, J.F., et al. The presence of STAT1-positive tumor-associated macrophages and their relation to outcome in patients with follicular lymphoma. Haematologica 91 (2006), 1605–1612.
126. [126] Bellucci, R., Martin, A., Bommarito, D., Wang, K., Hansen, S.H., Freeman, G.J., et al. Interferon-gamma-induced activation of JAK1 and JAK2 suppresses tumor cell susceptibility to NK cells through upregulation of PD-L1 expression. Oncoimmunology, 4, 2015, e1008824.
127. [127] Liu, J., Hamrouni, A., Wolowiec, D., Coiteux, V., Kuliczkowski, K., Hetuin, D., et al. Plasma cells from multiple myeloma patients express B7–H1 (PD-L1) and increase expression after stimulation with IFN-{gamma} and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway. Blood 110 (2007), 296–304.
128. [128] Loke, P., Allison, J.P., PD-L1 and PD-L2 are differentially regulated by Th1 and Th2 cells. Proc. Natl. Acad. Sci. USA 100 (2003), 5336–5341.
129. [129] Romberg, N., Morbach, H., Lawrence, M.G., Kim, S., Kang, I., Holland, S.M., et al. Gain-of-function STAT1 mutations are associated with PD-L1 overexpression and a defect in B-cell survival. J. Allergy Clin. Immunol. 131 (2013), 1691–1693.
130. [130] Kovacic, B., Stoiber, D., Moriggl, R., Weisz, E., Ott, R.G., Kreibich, R., et al. STAT1 acts as a tumor promoter for leukemia development. Cancer Cell 10 (2006), 77–87.
131. [131] Messina, N.L., Banks, K.M., Vidacs, E., Martin, B.P., Long, F., Christiansen, A.J., et al. Modulation of antitumour immune responses by intratumoural Stat1 expression. Immunol. Cell Biol. 91 (2013), 556–567.
132. [132] Khodarev, N.N., Beckett, M., Labay, E., Darga, T., Roizman, B., Weichselbaum, R.R., STAT1 is overexpressed in tumors selected for radioresistance and confers protection from radiation in transduced sensitive cells. Proc. Natl. Acad. Sci. USA 101 (2004), 1714–1719.
133. [133] Khodarev, N.N., Minn, A.J., Efimova, E.V., Darga, T.E., Labay, E., Beckett, M., et al. Signal transducer and activator of transcription 1 regulates both cytotoxic and prosurvival functions in tumor cells. Cancer Res. 67 (2007), 9214–9220.
134. [134] Tsai, M.H., Cook, J.A., Chandramouli, G.V., DeGraff, W., Yan, H., Zhao, S., et al. Gene expression profiling of breast, prostate, and glioma cells following single versus fractionated doses of radiation. Cancer Res. 67 (2007), 3845–3852.
135. [135] Duarte, C.W., Willey, C.D., Zhi, D., Cui, X., Harris, J.J., Vaughan, L.K., et al. Expression signature of IFN/STAT1 signaling genes predicts poor survival outcome in glioblastoma multiforme in a subtype-specific manner. PLoS One, 7, 2012, e29653.
136. [136] Weichselbaum, R.R., Ishwaran, H., Yoon, T., Nuyten, D.S., Baker, S.W., Khodarev, N., et al. An interferon-related gene signature for DNA damage resistance is a predictive marker for chemotherapy and radiation for breast cancer. Proc. Natl. Acad. Sci. USA 105 (2008), 18490–18495.
137. [137] Khodarev, N.N., Roizman, B., Weichselbaum, R.R., Molecular pathways: interferon/stat1 pathway: role in the tumor resistance to genotoxic stress and aggressive growth. Clin. Cancer Res. 18 (2012), 3015–3021.
138. [138] Boelens, M.C., Wu, T.J., Nabet, B.Y., Xu, B., Qiu, Y., Yoon, T., et al. Exosome transfer from stromal to breast cancer cells regulates therapy resistance pathways. Cell 159 (2014), 499–513.
139. [139] Stronach, E.A., Alfraidi, A., Rama, N., Datler, C., Studd, J.B., Agarwal, R., et al. HDAC4-regulated STAT1 activation mediates platinum resistance in ovarian cancer. Cancer Res. 71 (2011), 4412–4422.
140. [140] Pitroda, S.P., Wakim, B.T., Sood, R.F., Beveridge, M.G., Beckett, M.A., MacDermed, D.M., et al. STAT1-dependent expression of energy metabolic pathways links tumour growth and radioresistance to the Warburg effect. BMC Med., 7, 2009, 68.
141. [141] Warburg, O., On the origin of cancer cells. Science 123 (1956), 309–314.
142. [142] Ward, P.S., Thompson, C.B., Metabolic reprogramming: a cancer hallmark even warburg did not anticipate. Cancer Cell 21 (2012), 297–308.
143. [143] Kaewpiboon, C., Srisuttee, R., Malilas, W., Moon, J., Oh, S., Jeong, H.G., et al. Upregulation of Stat1-HDAC4 confers resistance to etoposide through enhanced multidrug resistance 1 expression in human A549 lung cancer cells. Mol. Med. Rep. 11 (2015), 2315–2321.
144. [144] Ambjorn, M., Ejlerskov, P., Liu, Y., Lees, M., Jaattela, M., Issazadeh-Navikas, S., IFNB1/interferon-beta-induced autophagy in MCF-7 breast cancer cells counteracts its proapoptotic function. Autophagy 9 (2013), 287–302.
145. [145] Li, Y., Zhu, H., Zeng, X., Fan, J., Qian, X., Wang, S., et al. Suppression of autophagy enhanced growth inhibition and apoptosis of interferon-beta in human glioma cells. Mol. Neurobiol. 47 (2013), 1000–1010.
146. [146] Zhu, S., Cao, L., Yu, Y., Yang, L., Yang, M., Liu, K., et al. Inhibiting autophagy potentiates the anticancer activity of IFN1@/IFNalpha in chronic myeloid leukemia cells. Autophagy 9 (2013), 317–327.
147. [147] Liang, J., Piao, Y., Henry, V., Tiao, N., de Groot, J.F., Interferon-regulatory factor-1 (IRF1) regulates bevacizumab induced autophagy. Oncotarget 6 (2015), 31479–31492.
148. [148] Wang, S., Patsis, C., Koromilas, A.E., Stat1 stimulates cap-independent mRNA translation to inhibit cell proliferation and promote survival in response to antitumor drugs. Proc. Natl. Acad. Sci. USA 112 (2015), E2149–E2155.
149. [149] Efimova, E.V., Liang, H., Pitroda, S.P., Labay, E., Darga, T.E., Levina, V., et al. Radioresistance of Stat1 over-expressing tumour cells is associated with suppressed apoptotic response to cytotoxic agents and increased IL6-IL8 signalling. Int. J. Radiat. Biol. 85 (2009), 421–431.
150. [150] Avalle, L., Pensa, S., Regis, G., Novelli, F., Poli, V., STAT1 and STAT3 in tumorigenesis: a matter of balance. JAKSTAT 1 (2012), 65–72.
151. [151] Regis, G., Pensa, S., Boselli, D., Novelli, F., Poli, V., Ups and downs: the STAT1:STAT3 seesaw of Interferon and gp130 receptor signalling. Semin. Cell Dev. Biol. 19 (2008), 351–359.
152. [152] Lai, P.S., Rosa, D.A., Magdy Ali, A., Gomez-Biagi, R.F., Ball, D.P., Shouksmith, A.E., et al. A STAT inhibitor patent review: progress since. Expert Opin. Ther. Pat. 2015 (2011), 1–25.
153. [153] Szelag, M., Czerwoniec, A., Wesoly, J., Bluyssen, H.A., Identification of STAT1 and STAT3 specific inhibitors using comparative virtual screening and docking validation. PLoS One, 10, 2015, e0116688.
154. [154] Zitvogel, L., Galluzzi, L., Kepp, O., Smyth, M.J., Kroemer, G., Type I interferons in anticancer immunity. Nat. RevImmunol. 15 (2015), 405–414.
155. [155] Balachandran, S., Adams, G.P., Interferon-gamma-induced necrosis: an antitumor biotherapeutic perspective. J. Interferon. Cytokine Res. 33 (2013), 171–180.
156. [156] Stiff, A., Carson, W. III, Investigations of interferon-lambda for the treatment of cancer. J. Innate. Immun. 7 (2015), 243–250.
157. [157] Sawant, D.V., Hamilton, K., Vignali, D.A., Interleukin-35: expanding its job profile. J. Interferon. Cytokine Res. 35 (2015), 499–512.
158. [158] Yoshimoto, T., Chiba, Y., Furusawa, J., Xu, M., Tsunoda, R., Higuchi, K., et al. Potential clinical application of interleukin-27 as an antitumor agent. Cancer Sci. 106 (2015), 1103–1110.
159. [159] Davis, M.R., Zhu, Z., Hansen, D.M., Bai, Q., Fang, Y., The role of IL-21 in immunity and cancer. Cancer Lett. 358 (2015), 107–114.